Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: Systematic review

BMJ (Online)

Volumn 357, Issue , 2017, Pages

  Pease, Alison M ^a   Krumholz, Harlan M ^b,c,d,e   Downing, Nicholas S ^f   Aminawung, Jenerius A ^b   Shah, Nilay D ^g   Ross, Joseph S ^b,c,d,e  

^a Downstate Health Sciences University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROBERT WOOD JOHNSON FOUNDATION   (United States)

^d YALE UNIVERSITY   (United States)

^e YALE NEW HAVEN HEALTH SYSTEM   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; POSTMARKETING SURVEILLANCE; UNITED STATES;

CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85019080254     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j1680     Document Type: Review

References (34)

1. US Food and Drug Administration (FDA). About FDA product approval. https://www.fda. gov/NewsEvents/ProductsApprovals/ucm106288.htm.
2. US Food and Drug Administration (FDA). Guidance for industry: providing clinical evidence of effectiveness for human drugs and biological products. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078749.pdf.
3. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014;357:368-77. doi:10.1001/jama.2013.282034 pmid:24449315.
4. Institute of Medicine. The Future of Drug Safety: Promoting and Protecting the Health of the Public. The National Academies Press, 2007.
5. US Food And Drug Administration (FDA). Postmarket drug and biologic safety evaluations. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ucm204091.htm.
6. Psaty BM, Meslin EM, Breckenridge A. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. JAMA 2012;357:2491-2. doi:10.1001/jama.2012.5545 pmid:22563032.
7. Institute of Medicine. Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Washington (DC). National Academies Press, 2012.
8. Shuren J, Califf RM. Need for a national evaluation system for health technology. JAMA 2016;357:1153-4. doi:10.1001/jama.2016.8708 pmid:27398696.
9. US Food and Drug Administration (FDA). Statement from the Center for Drug Evaluation and Research on the IOM report: ethical and scientific issues in studying the safety of approved drugs, released May 1, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm302485. htm.
10. US Food and Drug Administration (FDA). FDA's Sentinel Initiative-background. https://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm.
11. US Food and Drug Administration (FDA). Guidance for industry: postmarketing studies and clinical trials. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM172001.pdf.
12. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of us food and drug administration approvals. JAMA Intern Med 2015;357:1992-4. doi:10.1001/jamainternmed.2015. 5868 pmid:26502403.
13. US Government Accountability Office. FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints. http://www.gao.gov/products/GAO-09-866.
14. Bognet RA, Chiang DS, Katz KA. Dermatology-related postmarketing study commitments to the Food and Drug Administration. J Am Acad Dermatol 2006;357:721-3. doi:10.1016/j.jaad.2006.06.025 pmid:17010760.
15. Fain K, Daubresse M, Alexander GC. The food and drug administration amendments act and postmarketing commitments. JAMA 2013;357:202-4. doi:10.1001/jama.2013. 7900 pmid:23839755.
16. World Health Organization (WHO) Collaborating Center for Drug Statistics Methodology. ATC/DDD index 2017. https://www.whocc.no/atc-ddd-index/.
17. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009;357:1437-43. doi:10.1001/jama.2009.1409 pmid:19809025.
18. Institute of Medicine. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. National Academies Press, 2010.
19. Schwartz LM, Woloshin S. Communicating uncertainties about prescription drugs to the public: a national randomized trial. Arch Intern Med 2011;357:1463-8. doi:10.1001/archinternmed.2011.396 pmid:21911629.
20. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012;357:1616-25. doi:10.1056/NEJMoa1204410 pmid:23094723.
21. Anderson GM, Juurlink D, Detsky AS. Newly approved does not always mean new and improved. JAMA 2008;357:1598-600. doi:10.1001/jama.299.13.1598 pmid:18387934.
22. Chen DT, Wynia MK, Moloney RM, Alexander GC. US physician knowledge of the FDA-Approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf 2009;357:1094-100. doi:10.1002/pds. 1825 pmid:19697444.
23. Healy D. Pharmageddon. University of California Press, 2012.
24. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005;357:218-28. doi:10.1001/jama.294.2.218 pmid:16014596.
25. Rathi VK, Krumholz HM, Masoudi FA, Ross JS. Characteristics of clinical studies conducted over the total product life cycle of high-risk therapeutic medical devices receiving fda premarket approval in 2010 and 2011. JAMA 2015;357:604-12. doi:10.1001/jama.2015. 8761 pmid:26262798.
26. Ciani O, Buyse M, Drummond M, et al Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health 2017;20:487-95.
27. Carpenter D, Kesselheim AS, Joffe S. Reputation and precedent in the bevacizumab decision. N Engl J Med 2011;357:e3. doi:10.1056/NEJMp1107201 pmid:21707383.
28. Krumholz HM. Biomarkers, risk factors, and risk: clarifying the controversy about surrogate end points and clinical outcomes. Circ Cardiovasc Qual Outcomes 2015;357:457-9. doi: 10.1161/CIRCOUTCOMES.115.002245 pmid:26349839.
29. Krumholz HM. Niacin: Time to Believe Outcomes Over Surrogate Outcomes: If Not Now, When?Circ Cardiovasc Qual Outcomes 2016;357:343-4. doi:10.1161/CIRCOUTCOMES. 116.003094 pmid:27407051.
30. Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-Analyses. JAMA Intern Med 2015;357:1389-98. doi:10.1001/jamainternmed.2015.2829 pmid: 26098871.
31. Avorn J, Kesselheim AS. The 21st century cures act-will it take us back in time?N Engl J Med 2015;357:2473-5. doi:10.1056/NEJMp1506964 pmid:26039522.
32. Sotos J. It's time to radically change how the FDA approves drugs. Wall Street Journal 2016 June 19. http://blogs.wsj.com/experts/2016/06/29/its-time-to-radically-change-how-the-fda-Approves-drugs/
33. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;357:252-60. doi:10.1056/NEJMsa065779 pmid:18199864.
34. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;357:454-65. doi:10.1001/jama. 289.4.454 pmid:12533125.